At a glance
ClinicalIndex Comparison RecordN/ACompleted· 69 enrolled
Drug / intervention
Estrogens, Conjugated (USP) +1 moredrug
Likely dose
Estrogens, Conjugated (USP) 0.5gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Clinical Trial Comparing Vaginal Laser Therapy to Vaginal Estrogen Therapy in Women With Genitourinary Syndrome of Menopause
In Brief
A clinical study evaluating CO2 fractionated vaginal laser and Estrogens, Conjugated (USP) for Atrophic Vaginitis and Menopause. Completed, enrolled 69 participants across 6 sites.
Detailed Summary
This is a multi-centered, randomized prospective single blinded clinical trial comparing CO2 fractionated vaginal laser therapy and vaginal estrogen cream therapy in the treatment of vulvovaginal atrophy/GSM.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrophic Vaginitis, Menopause
CountriesUnited States
CollaboratorsFoundation for Female Health Awareness
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartMar 2016
Primary CompletionDec 2018
TodayJul 2026
First PostedFeb 25, 2016
Enrollment StartMar 1, 2016
Primary CompletionDec 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 10.4 years ago
Interventions
CO2 fractionated vaginal laserdevice
Intravaginal treatment with fractional microablative CO2 laser at baseline, 6 weeks and 3 months
Estrogens, Conjugated (USP)drug
Conjugated estrogen cream 0.5g (equivalent of 0.625 mg of conjugated estrogen) daily for two weeks then twice weekly for 24 weeks